WINNIPEG, Manitoba — September 16, 2025 — Leads & Copy — Kane Biotech Inc. (TSX-V:KNE) has announced the completion of a U.S. Food and Drug Administration (FDA) 510(k) clearance submission for its revyve® Antimicrobial Wound Cleanser.
The wound cleanser is the company’s third product in its revyve product line, and is complementary to Kane’s revyve Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray products. The new product will provide irrigation for cleansing acute and chronic wounds to decrease bacterial load and remove loose material. The cleanser formulation is based on revyve Antimicrobial Wound Gel.
The annual U.S. market size for wound cleansers exceeded $200M USD in 2024.
Dr. Robert Huizinga, Interim CEO, rhuizinga@kanebiotech.com, (780) 970-1100
Ray Dupuis, Chief Financial Officer, rdupuis@kanebiotech.com, (204) 298-2200
Source: Kane Biotech Inc.
